Efficacy and Safety of Non-recommended Dose of New Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Front Cardiovasc Med · 2021 · PMC8733406 · PMID 35004891

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginal significanceno p-value reported

Nevertheless, the all-cause mortality events patients were increased in patients receiving high dose rivaroxaban (RR = 1.72, 95% CI 1.00–2.97, P = 0.05), albeit at marginal significance levels ( Table 8 ).

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.